Kymera Therapeutics, Inc. Common Stock (KYMR) Financials
Key financial figures for Kymera Therapeutics, Inc. Common Stock (Q2 2026).
- Revenue
- $65M
- Net Income
- -$61M
- EPS
- $-0.62
- Total Assets
- $1.6B
- Operating Cash Flow
- -$54M
Full income statement, balance sheet, and cash flow for Kymera Therapeutics, Inc. Common Stock on SentiSense.